Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

Diagnosing atopic dermatitis is a matter of just ruling out all other causes of itching, which can be somewhat difficult at ...

Detailed price information for Devonian Health Group Inc (GSD-X) from The Globe and Mail including charting and trades.

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases. The global ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...